Main Article Content


The wound healing process is major cause of glaucoma surgery failure and enhances the incapability of controlling the IOP. This aim of study was to evaluate the angiogenesis effect of Bevacizumab injection on the amount and density of blood vessels in the rabbit model after trabeculectomy. It was a true experimental study using 16 eyes of 16 New Zealand White Rabbit (Oryctolagus cuniculus) that divided into two groups. The control group was treated with 0.05 ml of Balanced Saline Solution (BSS). The experimental group was treated with subconjunctival injection of 1.25 mg Bevacizumab in 0.05 BSS. All rabbit was sacrificed, and the eye was enucleated. Thus, the bleb area was dissected after 14 days. Histopathological analysis was performed to evaluate the amount and density of blood vessels. The mean amount of blood vessels in the control group was 22.63 ± 11.02, and the experimental group was 14,75 ± 4.92 (p=0.043). The mean of blood vessel density in the control group was 19.10 ± 1.69 %, and the experimental group was 16.53 ± 2.90 % (p=0.029)%. There was a statistically significant difference between the two groups (p<0.05). Subconjunctival bevacizumab in the rabbit model reduces the amount and density of blood vessels compared with subconjunctival BSS injection.


Angiogenesis bevacizumab amount of blood vessel density of blood vessel trabeculectomy

Article Details

How to Cite
Nurwasis, N., Yuliawati, D., Komaratih, E., & Heriyawati, H. (2019). The Effect of Subconjunctival Bevacizumab on Angiogenesis in Rabbit Model. Folia Medica Indonesiana, 55(4), 290–294.


  1. Cioffi GA, Durcan FJ, Girkin CA, Gupta, N Piltz-Seymour JR, Samuelson TW (2015). Basic and clinical science course: Glaucoma. San Fransisco, American Academy of Ophthalmology
  2. How A, Chua JL, Charlton A, Su R, Lim M, Kumar RS, Crowston JG, Wong TT (2010). Combined treatment with bevacizumab and s-fluorouracil attenuates the postoperative scarring response after experimental glaucoma filtration surgery. Invest Ophthalmol Vis Sci 51, 928-932
  3. Lama PJ, Fechner RD (2003). Antifibrotics and Wound Healing in Glaucoma Surgery. Surv Ophthalmol 48, 314-346
  4. Li Z, Bergen TV, Veire SV, Vel IV, Moreau H, Dewerchin M, Maudgal PC, Zeyen T, Spileers, W, Moons L, Stalmans I (2009). Inhibition of Vascular Endothelial Growth Factor Reduces Scar Formation after Glaucoma Filtration Surgery. Investigative Ophthalmology & Visual Science 50, 5217-5225
  5. Memarzadeh F, Varma R, Lin LT, Parikh JG, Dustin L, Alcaraz A, Eliott D (2009). Postoperative Use of Bevacizumab as an Antifibrotic Agent in Glaucoma Filtration Surgery in the Rabbit. Invest Ophthalmol Vis Sci 50, 3233-37
  6. Mietz H (2004). Wound Modulation in Glaucoma Surgery dalam Ghren, F. & Stamper, R. (Eds.). Essential in Ophthalmology: Glaucoma. Berlin, Springer-Verlag
  7. Ozgonul C, Mumcuoglu T, Gunal A (2014). The effect of bevacizumab on wound healing modulation in an experimental trabeculectomy model. Current Eye Research 39, 451-459
  8. Quigley H, Broman AT (2006). The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmology 90, 262-267
  9. Sheha, H. (2011). Update on modulating wound healing in trabeculectomy. In S Rumelt (Ed.). Glaucoma-Basic and Clinical Concept. Intech. Available at http:// modulating-wound-healing- in-trabeculectomy. Accessed July 9, 2019.
  10. Skuta GL, Parrish RK (1987). Wound healing in glaucoma filtration surgery. Surv of Ophthalmology 32, 149-70
  11. Stamper RL, Lieberman MF, Drake MV (2009). Introduction and classification of the glaucomas dalam RL Stamper, MF Lieberman, MV Drake (Eds.). Becker-Schaeffer’s Diagnosis and Therapy of the Glaucomas (8th Ed.). UK, Mosby Elsevier
  12. Valerie Gerriets, Anup Kasi (2019). Bevacizumab. USA, StatPearls Publishing LLC.
  13. Xiaoyan Liu, MM Liang Du PhD, Ni Li MD (2016). The effects of bevacizumab in augmenting trabeculectomy for glaucoma: A systematic review and meta-analysis of randomized controlled trials. Medicine 95, 15